Anna R. Hayden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna R. Hayden has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Alina S. Gerrie
Department of Medical Oncology, British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, Canada
1 shared publicationAndre Mattman
Department of Pathology and Laboratory Medicine University of British Columbia Vancouver Canada
1 shared publicationDavid Dix
Division of Hematology, Oncology and Bone Marrow Transplant, Department of Paediatrics University of British Columbia Vancouver BC Canada
1 shared publicationDavid W. Scott
Department of Medical Oncology, British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, Canada
1 shared publicationDerrick G. Lee
Department of Math, Statistics, and Computer Science, St. Francis Xavier University, Antigonish, NS, Canada
1 shared publication- Diego Villa
BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada
1 shared publication
Latest Publications
- Open Access
Etoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes
Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.
Open AccessEtoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes
Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.
- 10 December 2019
- Published by Wiley in British Journal of Haematology
- Vol. 189 (1) , 122-127
Validation of a simplified international prognostic score (IPS‐3) in patients with advanced‐stage classic Hodgkin lymphoma
Summary: A novel prognostic score (IPS‐3), comprised of only three of the seven IPS‐7 indicators (age ≥45, stage IV, haemoglobin <105 g/l), was recently proposed as a simplified model for advanced‐stage classic Hodgkin lymphoma (cHL). We aimed to validate this model in advanced‐stage cHL patients treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in British Columbia. The estimated five‐year freedom from progression (FFP) for scores of 0, 1, 2 and 3 were very similar to the original report at 84%, 76%, 72% and 68% respectively. The IPS‐3 score is highly reproducible in this independent dataset and its simplicity makes it appealing for everyday clinical practice.
- 10 December 2019
- Published by Wiley in British Journal of Haematology
- Vol. 189 (1) , 122-127
Validation of a simplified international prognostic score (IPS‐3) in patients with advanced‐stage classic Hodgkin lymphoma
Summary: A novel prognostic score (IPS‐3), comprised of only three of the seven IPS‐7 indicators (age ≥45, stage IV, haemoglobin <105 g/l), was recently proposed as a simplified model for advanced‐stage classic Hodgkin lymphoma (cHL). We aimed to validate this model in advanced‐stage cHL patients treated with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in British Columbia. The estimated five‐year freedom from progression (FFP) for scores of 0, 1, 2 and 3 were very similar to the original report at 84%, 76%, 72% and 68% respectively. The IPS‐3 score is highly reproducible in this independent dataset and its simplicity makes it appealing for everyday clinical practice.